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ABSTRACT
Purpose: Prostate cancer (PCa) has a highly heterogeneous outcome. Beyond 
Gleason Score, Prostate Serum Antigen and tumor stage, nowadays there are no 
biological prognostic factors to discriminate between indolent and aggressive tumors.
The most common known genomic alterations are the TMPRSS-ETS translocation 
and mutations in the PI3K, MAPK pathways and in p53, RB and c-MYC genes.
The aim of this retrospective study was to identify by next generation sequencing 
the most frequent genetic variations (GVs) in localized and locally advanced PCa 
underwent prostatectomy and to investigate their correlation with clinical-pathological 
variables and disease progression.
Results: Identified non-synonymous GVs included TP53 p.P72R (78% of tumors), 
two CSFR1 SNPs, rs2066934 and rs2066933 (70%), KDR p.Q472H (67%), KIT p.M541L 
(28%), PIK3CA p.I391M (19%), MET p.V378I (10%) and FGFR3 p.F384L/p.F386L 
(8%). TP53 p.P72R, MET p.V378I and CSFR1 SNPs were significantly associated with 
the HI risk group, TP53 and MET variations with T≥T2c. FGFR3 p.F384L/p.F386L was 
correlated with T≤T2b. MET p.V378I mutation, detected in 20% of HI risk patients, 
was associated with early biochemical recurrence.
Experimental design: Nucleic acids were obtained from tissue samples of 30 
high (HI) and 30 low-intermediate (LM) risk patients, according to D’Amico criteria. 
Genomic DNA was explored with the Ion_AmpliSeq_Cancer_Hotspot_Panel_v.2 
including 50 cancer-associated genes. GVs with allelic frequency (AF) ≥10%, affecting 
protein function or previously associated with cancer, were correlated with clinical-
pathological variables.
Conclusion: Our results confirm a complex mutational profile in PCa, supporting 
the involvement of TP53, MET, FGFR3, CSF1R GVs in tumor progression and 
aggressiveness.
INTRODUCTION
Prostate cancer (PCa) is the most common type of 
cancer in men, with nearly 220,000 new cases expected in 
2015 in USA [1]. The widespread use of serum prostate 
specific antigen (PSA) as a screening tool led to the 
increased frequency of PCa diagnoses. A subgroup of 
patients with extremely localized PCa may be potentially 
over-treated because only a proportion will develop a 
clinically detectable disease during their lifespan. PCa 
is extremely heterogeneous, ranging from a chronic 
indolent illness to an aggressive rapidly fatal malignancy. 
Beyond the classical prognostic factors of tumor stage (T), 
PSA level and Gleason score (GS), to date there are no 
biological prognostic factors able to discriminate between 
indolent and aggressive tumors. The abovementioned 
clinical prognostic factors allow clinicians to categorize 
patients into broad risk groups (low, intermediate and 
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high risk) but they incompletely explain the observed 
heterogeneity of clinical outcome [2]. Moreover, specific 
pathological assessments as, for instance, the GS is 
operator-dependent and inter-observer variability has been 
reported. Therefore, new prognosticators are needed to 
improve clinician’s skill in predicting individual likelihood 
of each PCa to progress and metastasize.
Advances in sequencing technologies generated a 
huge amount of data about the mutational events underlying 
development, progression and treatment response in 
cancer. Even if the spectrum of genetic alterations in PCa 
is heterogeneous, these mutations are more frequently 
reported in the PI3K and MAPK pathways and in p53, RB 
and c-MYC genes, all known to affect tumorigenesis in a 
wide spectrum of tumors, while there are others genetic 
alterations more specifically reported in PCa [3]. The vast 
majority of PCa harbors ETS rearrangements, generally as 
TMPRSS-ERG fusion [4]. In addition, PTEN and TP53 
tumor suppressor genes are deleted in about 20-40% of 
PCa while Speckle-Type POZ Protein mutations occur in 
about 10% of the samples [5, 6].
In this retrospective study, formalin-fixed, paraffin-
embedded (FFPE), prostatectomy specimens from 60 patients 
with localized or locally advanced PCa having clinical 
annotates were collected. Tumor samples were analyzed 
by next generation sequencing (NGS) in order to test 
the most frequent genetic mutations reported in cancers 
and to investigate their potential correlation with clinical 
pathological variables and disease progression.
RESULTS
Sixty cases of localized or locally advanced PCa 
submitted to radical prostatectomy at San Luigi Gonzaga 
Hospital (Orbassano, Turin) were retrospectively 
extracted from an institutional clinical database. Based 
on PSA, GS and T, using the D’Amico criteria, tumors 
were categorized as high risk (HI, PSA>20 ng/ml, GS>7, 
T2c-T3, n=30) or low-intermediate risk (LM, low risk: 
PSA<10 ng/ml, GS <7, T1-T2a; intermediate risk: PSA: 
10-20 ng/ml, GS=7, T2b, n=30).
Patients’ characteristics are shown in Table 1 . 
Median age was 66 (range: 49-76), median PSA before 
prostatectomy was 7 ng/ml (range: 3.2-21); 29 patients 
(48.3%) had GS=6, 28 (46.6%) GS=7 and 3 (5.1%) had 
GS=8. TMPRSS2:ERG fusion was found in 14/29 (48%) 
HI patients and in 5/26 LM (19%). AR expression was 
detectable in all samples analyzed but was not statistically 
different between two patient groups (p=0.9).
Older age (> median), PSA at diagnosis > 10ng, 
Gleason Score ≥7, T≥2c, perineural/vascular invasion, 
pelvic lymphadenectomy, biochemical recurrence 
and TMPRSS2:ERG translocation were significantly 
associated with the HI group (Table 1). Gleason Score 
≥7, T≥2c, vascular invasion, pelvic lymphadenectomy 
and PSA after prostatectomy >0.02 ng were significantly 
associated with early progression time. Gleason Score, 
vascular invasion and PSA after prostatectomy were 
independent predictors of early progression time (Gleason 
Score: p=0.02, HR=5.4 95% CI [1.24-23.37], vascular 
invasion: p=0.045, HR 3.86 95% CI [1.03-14.5], PSA 
after prostatectomy: p≪0.01, HR 121.4 95% CI [17.41-
847.31]).
CHP2 genetic profile
DNA was successfully extracted, amplified and 
sequenced from all samples. Non-synonymous genetic 
variations (GVs) with allelic frequency (AF) ≥10% are 
reported in Figure 1 and complete information for all 
genes included in analysis are presented in Supplementary 
Table S1. The most frequent non-synonymous GVs 
identified were TP53 p.P72R (COSM250061) in 78% of 
tumors, followed by two SNPs (rs2066934, rs2066933), 
within the 3’UTR of the CSFR1 gene in 70% of tumors, 
KDR p.Q472H (COSM149673) in 67%, KIT p.M541L 
(COSM28026) in 28%, PIK3CA p.I391M (COSM328028) 
in 19%, MET p.V378I (COSM3411512) in 10% and 
FGFR3 p.F384L/p.F386L (COSM724,COSM1539830) 
in 8%. The GVs at TP53 p.P72R, CSFR1 (rs2066934, 
rs2066933) and MET p.V378I were significantly 
associated with the HI risk group (p=0.027, p=0.047 
and p=0.011, respectively). Moreover, TP53 p.P72R and 
MET p.V378I were also correlated to T≥T2c (p=0.032 
and p=0.047, respectively). Conversely, genetic variation 
FGFR3 p.F384L/p.F386L was correlated with T≤T2b 
(p=0.004) and KDR p.Q472H with tumors lacking 
vascular invasion (p=0.021). Among synonymous GVs 
only the FGFR3 SNP rs3135898, found in 11 patients 
(18%), was significantly correlated to the HI group and 
T≥T2c tumors (p=0.042 and p=0.029, respectively). 
MET p.V378I mutation, clustered among 6 patients of 
the HI risk group (20%), was correlated to early PCa 
recurrence (p=0.02, HR 3.54 95% CI [1.38-44.98]). At the 
multivariable analysis, this mutation was an independent 
predictor of early recurrence of borderline statistical 
significance (p=0.055, HR 5.76 95% CI [0.97-34.31]) 
(Table 2).
Two groups of tumors were identified according to 
the CHP2 mutational profile findings: tumors with few 
non-synonymous GVs and tumors with several GVs in 
many genes. Independently from the risk class, the second 
group was associated with high TP53 mutational rate. To 
assess the robustness of this preliminary observation, the 
entire group of patients was clustered for “deleterious” 
or “tolerated” TP53 mutations, using a combination of 
PolyPhen-2 and SIFT software. These bioinformatic 
tools apply statistical algorithms based on sequence- and 
structure- information to predict the effect of GVs on 
proteins functionality/activity. As shown in Figure 2 and 3, 
both using the ≥10% and the ≥5% AF filter, patients with 
a high mutation rate were often included in “TP53 GVs 
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Table 1: Clinical pathological features in high and low/intermediate risk prostate cancer patients
Tot N (%) High (30) Low/Med (30) P value Fisher 
Test
Age (median: 66 Years) <0.01
Under 30 (50) 9 21
Over 30 (50) 21 9
PSA at diagnosis 0.02
≤10 46 (76.6) 18 28 (>10 ng)
10-20 10 (16.7) 8 2
>20 4 (6.7) 1
PSA post prostatectomy 0.37
<0.02 50 (83.3) 23 27
≥0.02 10 (16.7) 7 3
Gleason Score ≪0.01
<7 28 (46.6) 6 22 (≥7)
=7 29 (48.3) 21 8
>7 3 (5.1) 3 0
Tumor Size (T) ≪0.01
T1-T2a 16 (26.6) 0 16 (≥2c)
T2b 14 (23.3) 1 13
T2c-T3 30 (50) 29 1
Perineural invasion 0.012
no 10 (16.7) 1 9
yes 50 (83.3) 29 21
Vascular invasion 0.03
no 43 (71.7) 18 27
yes 13 (21.7) 10 3
missing 4 (6.6)
Surgical margins 1
R0 53 (88.3) 26 27
R1 7 (11.7) 4 3
Pelvic Lymphadenectomy ≪0.01
no 38 (63.3) 10 28
yes 22 (36.7) 20 2
Biochemical recurrence <0.01
no 45 (75) 17 28
yes 15 (25) 13 2
ERG:TMPRSS2 0.03
no 41 (68.3) 16 25
yes 19 (31.7) 14 5
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Figure 1: Summary of genetic variations identified by NGS. Non synonymous/regulative variations identified in the 50 
cancer-associated genes with at least 10% of allelic frequency are summarized in figure. The blue blocks indicate patients with High risk 
of PCa-recurrence while the white blocks those patients with low/moderate risk.
Table 2: Main genetic variations identified in prostate cancer patients
Gene Chr Position Ref Alt Type AA 
Change
SNP ID COSMIC ID Patients 
affected
Corre­
lation
CSF1R chr5 149433596 T G UTR3 NA rs2066934 NA 42 High Risk
CSF1R chr5 149433597 G A UTR3 NA rs2066933 NA 42 High Risk
FGFR3 chr4 1806131 T C Non-Synonymous
p.F384L, 
p.F386L
rs17881656
COSM724, 
COSM1539830
5 T≤2b
FGFR3 chr4 1807922 G A intronic NA rs3135898 NA 11 High Risk, 
T≥2c
KDR chr4 55972974 T A Non-Synonymous p.Q472H rs1870377 COSM149673 28
Less 
invasive 
tumor
MET chr7 116340270 G A Non-Synonymous p.V378I NA COSM3411512 6
High Risk, 
T≥2c, short 
recurrence 
time
TP53 chr17 7579472 G C Non-Synonymous p.P72R rs1042522 COSM250061 47
High Risk, 
T≥2c
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Figure 2: CHP2 genetic variability in prostate cancer. The panel shows the heatmap of PCa samples, including only the non 
synonymous/regulative variations at ≥ 5% AF. The ≥ 5% filter was used only for graphic display. The blue tiles identify variations and color 
intensity is proportional to the number of variations observed in each PCa sample and indicated within the tile. Independently by the risk 
class, the group of cases having several GVs in many genes was associated with high TP53 mutational rate. Furthermore, only in a small 
subgroup of these high-mutated patients, the TMPRSS2-ERG translocation was detected (red star).
Figure 3: TP53 GVs deleterious correlate with high mutation rate patients. Both heatmaps represent PCa patients with only the 
non synonymous/regulative variations at ≥ 10% (left panel) or ≥ 5% AF (right panel). Blue tiles contain the number of variations identified, 
visualized by proportional color intensity, observed in each PCa sample. The entire group of patients was clustered for “deleterious” or 
“tolerated” TP53 mutations, using a combination of PolyPhen-2 and SIFT software. In both panels, representing the applied AF filters of 
≥10% and the ≥5%, respectively, patients with a high mutation rate were often included in “TP53 GVs deleterious group”.
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deleterious group” and only few of these tumors showed 
TMPRSS2:ERG translocation.
To highlight differences between HI and LM groups, 
the matrix of non-synonymous GVs (AF ≥10%) was also 
assessed by means of SAM-sequencing tools. This software 
allows detecting differences between two or more groups 
determining a false discovery rate (FDR) to increase 
robustness of data analyses. CSF1R GVs were associated 
to HI risk group and NOTCH1, IDH2, FGFR3 and STK11 
often altered in LM groups (Figure 4, upper panel). 
Interestingly, some of these non-synonymous GVs were 
enriched in limited gene regions corresponding to specific 
protein domain (Figure 4, lower panel) [7]. GVs for the 
FGFR3 gene were consistently clustered in I-set domain, 
P-kinase Domain and between these two regions, as well as 
at the end of coding sequence for NOTCH1, in the middle 
of STK11 kinase domain and in IDH2 iso_dh domain.
To assess the expression pattern of CHP2 genes 
the NGS RNA-sequencing analysis was tested. After 
normalization by AmpliSeqRNA plugin, 22 valid expression 
profiles for the HI and 29 for the LM group were obtained. 
SAM-sequencing software identified, between the HI and 
the LM groups, differentially expressed transcripts for 
FBXW7, JAK2, GNAQ (t-test p=0.001, p=0.02 and p=0.02, 
respectively). No correlation between CHP2 RNA expression 
and clinical-pathological characteristics was identified. An 
association between TP53 mRNA low levels and “TP53 
altered group” ≥5% AF was observed (p=0.02).
DISCUSSION
In the last 10 years, NGS boosted biological 
and biomedical knowledge facilitating multi-gene 
mutational profiling using extremely small amounts of 
DNA, including that obtained by FFPE. The expanding 
application of NGS techniques has the potential for 
accurately mapping the type and extent of gene mutations 
in several solid tumors including PCa. In this retrospective 
study, the feasibility of assessing mutational changes by 
NGS using FFPE tissue samples was investigated using 
Figure 4: SAM analysis and protein domains localization of detected GVs. The upper panel summarizes the results elaborated 
by means of SAM software and visualized through heatmap including non synonymous/regulative variations at ≥ 10% AF. CSF1R GVs 
were mainly identified in HI risk patients, in contrast NOTCH1, IDH2, FGFR3 and STK11 GVs were often observed in LM group. The 
MutationMapper software, which identifies protein regions affected by corresponding GVs, reflects the protein localization of such non-
synonymous GVs, being enriched, in LM cluster, in limited and specific domains (lower right panel).
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a commercially available panel of key cancer-associated 
genes. Despite the limited number of samples included 
in this study, some peculiarities in PCa GVs profile were 
identified. An enrichment for GVs in a quite restricted 
number of genes including TP53, CSF1R, KDR, KIT, 
ATM, PIK3CA, MET, EGFR, FGFR3, ranging from 90% 
to 30% of the analyzed samples, were documented and 
most of these genes were previously associated with PCa.
Genetic alterations in TP53 were the most common 
GVs and this observation agrees with previously published 
data that since early ‘90s documented TP53 mutations 
in PCa [8, 9]. Irrespective of risk stratification, we 
identified several alterations in this gene, some of which 
are already cancer-related and annotated in COSMIC 
database (Supplementary Table S1 ). In addition, patients 
with CHP2 high mutation rate display simultaneous 
“deleterious” TP53 mutations (Figure 2 and 3) and/or 
significant low levels of TP53 gene expression (p=0.02, 
GVs ≥5% AF). These data support the hypothesis of 
a reduced activity/expression of TP53 protein in PCa 
and suggest for its role in PCa tumorigenesis or tumor 
progression, as already suggested by others [9, 10]. High 
allelic variations at TP53 p.P72R, already identified in 
malignant pleural mesothelioma [11], were observed in 
PCa mainly in the HI risk group, suggesting its potential 
role as a risk factor. In agreement with our data, Zhang 
et al. showed that Caucasians with the Arg allele have an 
increased PCa risk [12]. A significant difference in the 
frequency of TP53 codon 72 variants between sporadic 
PCa and benign prostate hyperplasia was recently 
observed, implying that this polymorphism may have a 
role in tumor development [13]. In our study, we identified 
two SNPs in CSF1R gene, rs2066934 and rs2066933, 
mainly detected in HI risk group. Although these SNPs 
have been also recently reported in malignant pleural 
mesothelioma [11], scant information is available about 
these GVs. These two nucleotides trigger the 3’UTR 
region in a miRNA seed-complementary sequence, which 
could modulate response to imatinib by increasing CSF1R 
gene expression [14]. Two other studies which extensively 
explored NGS in advanced, castration resistant PCa did 
not detect any GVs in the CSF1R gene but differences in 
the disease setting and the NGS platforms used preclude 
any comparison [5, 6].
KIT p.M541L mutation, identified in about 30% of 
the tumors and without any relationship with the risk class, 
was already associated to clinical response to imatinib. 
In patients with aggressive fibromatosis harboring this 
mutation, a higher sensitivity to imatinib was initially 
observed but not confirmed in a subsequent study, possibly 
as the consequence of the rarity of this mutation in these 
rare tumors [15, 16]. Patients with chronic eosinophilic 
leukemia positive for KIT p.M541L showed clinical 
response to low dose imatinib [17]. In preclinical studies 
in PCa cells imatinib, alone or in combination with other 
cytotoxic therapies, showed a significant treatment effect 
[18–20]. Conversely, in clinical studies in patients with 
castration resistant PCa imatinib demonstrated only a 
modest activity [21–23]. These conflicting data between 
preclinical and clinical studies in PCa may be the result of 
a differential role of the CSF1R/KIT genetic alterations in 
patients and in cell lines. Our findings suggest additional 
studies testing the role of imatinib in genetically selected 
PCa patients.
The MET p.V378I mutation was detected in 6 
tumors of the HI risk group and associated with early 
PCa recurrence following radical surgery (Table 2). 
Whereas the proto-oncogene MET has been associated 
with PCa, the specific variation MET p.V378I, included 
in COSMIC database (COSM3411512), has not been 
extensively investigated. C-Met expression increases in 
advanced stages of the disease and more frequently in 
patients with bone metastases [24, 25]. In addition, c-MET 
protein expression is higher in poorly differentiated 
PCa with low PSA levels [26]. An inverse relationship 
between Androgen Receptor (AR) and c-MET has been 
already demonstrated [27] suggesting that a reduction of 
AR activity through androgen ablation may increase the 
expression of c-MET, directly contributing to androgen 
insensitivity and favoring tumor aggressiveness. 
Several clinical trials with different c-MET inhibitors 
(cabozantinib, tivantinib and other multi-target kinase 
inhibitors), have been recently performed [28–30] or are 
ongoing (NCT01428219, NCT01703065, NCT01630590, 
NCT01834651, NCT01812668, NCT01683994, 
NCT01519414), but the available data did not show any 
significant impact of these inhibitors on overall survival. 
These negative results could reflect the genetic variability 
highlighted in our study and the c-MET mutational status 
may potentially considered as a stratification factor 
in future studies aimed at evaluating the role c-MET 
inhibitors.
The genetic alterations in NOTCH1, IDH2, 
FGFR3 and STK11 more frequently reported in the LM 
risk group are located in regions that could influence 
protein functionality. Additional studies are needed to 
assess if GVs identified may deregulate or influence the 
corresponding gene expression/function. Retrospective 
studies showed a correlation between FGFR3 mutations 
and the development of good prognosis superficial bladder 
carcinoma [31, 32]. Interestingly in PCa FGFR3 mutations 
were associated with low-grade tumors. The F386L 
polymorphism has been reported in association with low-
grade tumors and early disease stage [33] and in our series 
the FGFR3 p.F384L/p.F386L was associated with T<T2b 
patients (p=0.004).
Several studies on PCa have investigated the 
association between TMPRSS2:ERG fusion gene and 
outcome reporting conflicting results [34]. In our study, 
the presence of this rearrangement was correlated with the 
risk of recurrence, being the fusion gene mostly detected 
in patients with a low mutation rate. This observation 
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suggests an involvement of TMPRSS2:ERG fusion gene 
in PCa aggressiveness independent from the gain of 
mutations. A previous study indicated that TMPRSS2-
ERG gene fusion is a common event and occurs early 
in the development of invasive PCa [35]. Another study 
indicated that ERG gene alterations represent an initiating 
event that favors epithelial atypia and further progression 
to high-grade prostatic intraepithelial neoplasia and cancer 
[36].
After performing the DNA sequencing analyses, 
we also conducted an RNA sequencing analysis to 
determine gene expression of the 50 genes included in 
CHP2. We detected that FBXW7, GNAQ and JAK2 were 
over-expressed in the HI risk group without showing 
any correlation between gene expression and clinical-
pathological characteristics. Additional investigation 
is needed to assess if these mRNA de-regulations may 
influence the protein expression and/or contribute to PCa 
development/progression.
We identified genetic markers potentially associated 
with disease pathogenesis, progression and response/
resistance to treatment. However the translation of these 
results to the development of clinical diagnostic tests 
and to patient stratification in clinical trial is critical. 
Significant challenges, such as intra-tumoral heterogeneity 
and multifocality in primary tumors, limits the application 
of genomic medicine in prostate cancer and hinder the 
generation of risk stratification tools that correlate clinical 
outcome with the genomic landscape. Large clinical trials 
are needed to prospectively validate the utility of genetic 
markers for the clinical decision making.
In conclusion, this is one of the first retrospective 
studies that tested the feasibility of NGS for PCa genetic 
characterization using FFPE archival material. Although 
the limited number of patients limits the statistical power 
of the analyses, the reported results are in agreement 
with previously published data suggesting a complex 
mutational pattern in PCa. In addition, our data support 
the involvement of TP53, MET, FGFR3, CSF1R 
GVs in PCa, mainly influencing tumor progression or 
aggressiveness. Some of these GVs, such as CSFR1 SNPs 
or KIT p.M541L may potentially contribute, if data will be 
confirmed in larger studies, to customized treatments with 
targeted therapies.
MATERIALS AND METHODS
Patients and tissue samples
Sixty cases of localized or locally advanced PCa 
submitted to radical prostatectomy at San Luigi Gonzaga 
Hospital (Orbassano, Turin) between September 2003 and 
May 2009, with enough leftover FFPE tissue available 
and detailed clinical annotates were retrospectively 
extracted from an institutional clinical database. Based 
on PSA, GS and T, using the D’Amico criteria, tumors 
were categorized as high risk (HI, PSA>20 ng/ml, GS>7, 
T2c-T3, n=30) or low-intermediate risk (LM, low risk: 
PSA<10 ng/ml, GS <7, T1-T2a; intermediate risk: PSA: 
10-20 ng/ml, GS=7, T2b, n=30).
Informed consent was previously obtained from 
each patient and the Institutional Review Board approved 
the study. All samples were de-identified and cases 
anonymized by a pathology staff member not involved in 
the study.
All samples were reviewed and classified according 
to UICC criteria [37].
RNA isolation from paraffin-embedded tissues 
and quantitative real-time PCR
Serial 10 μm sections were cut in RNase-free 
conditions. The specimens were stained with hematoxylin-
eosin, representative tumor areas were identified and 
isolated by means of microdissection using a scalpel at 
a magnification of 100x. RNA isolation was performed 
using commercially available RNA extraction kits 
for paraffin material according to the manufacturer’s 
instructions (High Pure RNA paraffine kit; Roche Applied 
Science, Germany).
Complementary DNA was transcribed using random 
hexamer primers (Roche Applied Science) and M-MLV 
reverse transcriptase (200 U/ml; Invitrogen, Carlsbad; CA) 
according to standard protocols.
Expression levels for all investigated genes and 
an internal reference gene (β-actin) were assessed using 
a fluorescence-based real-time detection method (ABI 
PRISM 7900 Sequence Detection System–Taqman; 
Applied Biosystems, Foster City, CA,). Primers for β-actin 
and for androgen receptor have been previously reported 
[38, 39]. For androgen receptor and ERG:TMPRSS2 
fusion gene TaqMan gene expression assays 
(AR: HS00171172_m1, TMPRSS2-ERG: HS003063375-
ft) were diluted 1:20 with 1X Taqman Universal PCR 
Master Mix to a final volume of 20 μL (all reagents from 
Applied Biosystems). Cycling conditions were 50°C for 2 
minutes and 95°C for 10 minutes followed by 46 cycles 
at 95°C for 15 seconds and 60°C for 1 minute. Relative 
gene expression levels were expressed as unit less ratios 
between 2 measurements (genes of interest/internal 
reference gene). Total RNAs (Stratagene, La Jolla, CA) 
were used as control calibrators on each plate.
Genomic DNA/total mRNA extraction and NGS
Nucleic acids for NGS were obtained from tissues 
after manual microdissection with enrichment for at least 
50% of neoplastic cells. Genomic DNA (gDNA) and total 
mRNA were extracted using AllPrep DNA/RNA FFPE Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s 
instructions. gDNA and mRNA were quantified using 
fluorometer Qubit platform (Invitrogen, Carlsbad, CA).
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NGS analyses were performed on the Ion Torrent 
Personal Genome Machine (PGM, Life Technologies, 
Grand Island, USA). Tumor samples were tested 
using a commercially available library kit (gDNA: Ion 
AmpliSeq Cancer Hotspot Panel v.2 (CHP2), mRNA: Ion 
AmpliSeq RNA Cancer Panel) to investigate 50 cancer-
associated genes (See Supplementary Table S1 ). Each 
amplicon library was generated starting from 10 ng of 
gDNA or mRNA, as indicated by the manufacturer, and 
barcoded with Ion Xpress Barcode Adaptors Kit (Life 
Technologies). DNA Library quantification was performed 
using the PCR quantification kit and the 7900HT real time 
PCR system (Life Technologies), diluted in nuclease-free 
water to obtain a final concentration of 100 pM. Emulsion 
PCR was performed on Ion PGM™ Template One Touch 
2 system (Life Technologies). The quality of the emulsion 
PCRs was measured using the Qubit IonSphere Quality 
control kit (Life Technologies). IonSphere Particles with 
DNA were isolated and sequenced on Ion 316 Chip using 
the Ion PGM™ Sequencing 200 Kit (Life Technologies). 
Only sample sequences with at least a quality score of 
AQ20 (1 misaligned base per 100 bases) were considered 
for further analyses.
DNA target sequencing
The inclusion criteria for the analyses mainly 
considered the coverage target for each sample and this 
value was set at a minimum average deep of 100 reads 
for each amplicon (whole coverage: min=18, max=3875, 
amplicons average=1190). Variant Caller plugin included 
in Torrent Suite Software v.4.2.1 was used to identify 
variations in target regions and genetic annotation was 
performed with Annovar software [40] (COSMIC database 
v.70, SNPs database v.138). Each of the identified genetic 
variation was coded according to “plus strand” of Human 
Genome assembly hg19. Some of the commonest genetic 
variations identified in the study were further validated and 
specific primers listed in CHP2 supplementary files were 
used for PCR. The quality of the resulting amplicons was 
checked by LabChip® GX (PerkinElmer, Waltham, MA, 
USA) and subsequently validated by Sanger sequencing. 
For the genetic variations in study, the correlation between 
Sanger and NGS was always ≥ 80%.
RNA target sequencing
AmpliSeqRNA plugin included in Torrent Suite 
Software v.4.2.1 was used to normalize expression levels 
of each amplicon in the RNA-sequencing analysis. 
Differentially expressed/mutated genes between the HI 
and LM risk groups were identified using the RNA-seq 
version of Significance Analysis of Microarray (SAMseq) 
included in the R package “samr”. The significant 
differential expression levels were subsequently tested in 
qPCR analysis.
Statistical analysis
Statistical correlation between gene variations with 
allelic frequency (AF) ≥10% and clinical-pathological 
features were investigated by Fisher exact test.
Time to progression (TTP) was defined as the time 
from the prostatectomy until the first evidence of disease 
progression, defined as confirmed PSA increase above 0.2 
ng /ml. The log rank test was used to assess differences 
between groups. The Cox proportional hazards regression 
model was performed to analyze independent prognostic 
factors and TTP. Only the variables that were found to be 
significant in the univariate analyses (p<0.05) were entered 
into the multivariable analysis to determine the most 
significant factors for predicting disease outcome. Statistical 
analysis was elaborated using R statistical software [41].
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